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Sapporo-Kosei General Hospital, Sapporo, JapanA B S T R A C TObjectives: Pegylated-interferon-α (IFN-α)-based therapies for viral
hepatitis C (HCV) are effective, but they are associated with several
adverse events (AEs). The primary objectives of this study were to
quantify the burden of IFN-α–based treatment and to measure the
prevalence and burden of IFN-α–related AEs in Japan. Methods: A
cross-sectional survey was administered online to patients with HCV
in 2013. Patients who were currently taking IFN-α–based therapy (n ¼
188) were compared with patients who were taking a liver protectant
but not IFN-α–based therapy (n ¼ 180) and with patients who were
untreated (n ¼ 365) on measures of health-related quality of life (using
the Hepatitis Quality of Life Questionnaire, version 2), work produc-
tivity, and health care resource use, controlling for sociodemographic
characteristics and health history. Among patients taking IFN-α–based
therapy, the prevalence and burden of AEs was examined on the same
set of health outcomes as noted above along with treatment satisfac-
tion and adherence. Results: Compared with untreated patients,
patients using IFN-α reported poorer health-related quality of lifesee front matter Copyright & 2014, International S
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0.(physical component summary score, 50.13 vs. 52.04; mental compo-
nent summary score, 44.12 vs. 47.97), more overall work impairment
(32.73 vs. 25.64), more physician visits in the past 6 months (14.51 vs.
8.36), and an increased likelihood of an emergency room visit (odds
ratio ¼ 7.25) and hospitalization (odds ratio ¼ 4.05) (all P o 0.05). The
mean number of AEs was 6.05 for patients using IFN-α. All AEs were
associated with poorer health outcomes (particularly the mental
component summary score), and most were also associated with
lower treatment satisfaction and medication adherence. Conclusions:
A signiﬁcant patient burden for IFN-α treatment itself and various AEs
was observed. The results suggest that effective, non-IFN-α–based
treatments may reduce the societal burden.
Keywords: adherence, adverse events, hepatitis C, interferon, quality
of life, resource use, satisfaction, work impairment.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hepatitis C virus (HCV) affects an estimated 170 million people
globally and 2 million people in Japan [1]. Partly because of the
use of nondisposable syringes for immunizations in the 1950s,
which resulted in widespread infection, the prevalence of HCV in
Japan peaks among those aged 60 to 70 years [2–4]. In a recent
study of voluntary blood donors, 7% of those 70 years or older
were infected with HCV [5]. Among symptomatic patients, 60% to
80% will develop chronic infection, which leads to an increased
risk of cirrhosis, hepatocellular carcinoma, and end-stage liverdisease [6]. Indeed, the prevalence of hepatocellular carcinoma in
Japan has increased over the past 50 years, with more than
300,000 patients dying each year; it is estimated that HCV is
related to 70% to 90% of these cases [3,7].
Pegylated interferon-α (IFN-α) plus ribavirin (RBV) combina-
tion therapy has been the mainstay of HCV treatment. Forty-
eight and 24 weeks of IFN-α þ RBV treatment for genotypes 1
and 2, respectively, have resulted in a sustained virologic
response for approximately 50% and 80% of patients, respec-
tively [8]. The success rate of HCV therapy is expected to
improve following the recent approval of telaprevir (TVR), aociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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recently approved direct-acting antiviral, has not been
approved for use in Japan). TVR is used in combination with
IFN-α þ RBV (i.e., IFN-α þ RBV þ TVR; “triple therapy”), resulting
in sustained virologic response rates of approximately 70%
among treatment-naive patients and is now considered the
new standard of care [7,8]. A signiﬁcant disadvantage of IFN-α–
based therapy (with or without TVR), however, is its poor safety
and tolerability proﬁle. Adverse events (AEs) include induced
bone marrow depression, ﬂu-like symptoms (e.g., fever, chills,
headaches, arthralgia, and myalgia), neuropsychiatric disorders
(e.g., severe fatigue, irritability, and apathy), neurological side
effects (e.g., seizures, parathesias, confusion, aphasia, cortical
blindness, delirium, and extrapyramidal syndromes marked by
ataxia and akathisia), and autoimmune syndromes (e.g., auto-
immune thyroiditis and diabetes) [9–12]. Among patients using
triple therapy, 70% experienced anemia and 80% developed a
rash [7].
IFN-α–related AEs have been shown to compromise health-
related quality of life and result in dose modiﬁcations or dis-
continuation [13,14]. In a multinational study by Ware et al. [15],
the health-related quality-of-life scores of all patients decreased
during IFN-α treatment and returned to pretreatment levels
during the 24 weeks after treatment. In another study, compared
with untreated patients with HCV, those treated with IFN-α
showed decrements in energy, physical mobility, and pain based
on the Nottingham Health Proﬁle questionnaire [16]. In examin-
ing health-related quality of life and IFN-α treatment, Dan et al.
[17] found that depression was the most consistent predictor of
health-related quality of life in patients. IFN-α treatment also
negatively impacts work productivity. Brook et al. [18] examined
the impact of HCV treatment with IFN-α and/or RBV on absentee-
ism and work productivity using longitudinal data from the
Human Capital Management Services Research Reference Data-
base. Treated employees had 0.52 more health-related work
absence days than did untreated employees (1.27 vs. 0.75 work-
days monthly) and incurred signiﬁcantly greater expenditures for
sick leave and short-term disability [18].
In sum, research has demonstrated that existing IFN-α–based
therapies including triple therapy are effective, but they are also
associated with various AEs. The impact of current IFN-α treat-
ment on patient burden is of particular importance in Japan
where the predominantly older patient population may be even
less likely to tolerate IFN-α–based treatment [13]. To date, there is
a lack of research examining the patient-reported treatment-
related burden of HCV in Japan. Thus, the primary objectives of
this study were to quantify the humanistic and economic burden
of IFN-α–based treatment and to measure the prevalence and
burden of IFN-α–related AEs.Methods
Data Source
The current study includes data from a 2013 online survey that
was administered to respondents of the Japan National Health
and Wellness Survey (NHWS). The NHWS is an annual general
health survey that includes questions on medical conditions,
symptoms, treatment information, and health outcomes among
other variables (N ¼ 30,000 per year). Respondents to the Japan
NHWS were recruited from an online panel using a stratiﬁed
random sample framework (with quotas based on sex and age) to
match the characteristics of the adult population in Japan.
Comparisons between the Japan NHWS and governmental sour-
ces are reported elsewhere [19]. To enhance sample sizes,
particularly of the IFN-α–treated population, members of thesame online panel that serves as the sample source for the Japan
NHWS were also contacted directly to participate. All respond-
ents who completed the survey were compensated in the form of
points, which could be exchanged for small items or used to enter
into a rafﬂe for larger prizes. Although there is no speciﬁc
monetary value to these points, it would approximate to less
than US $10. The protocol was reviewed and approved by an
institutional review board, and all respondents provided
informed consent.
Study Sample
Respondents who reported a diagnosis of HCV and were 20 years
or older were eligible for this study; respondents who reported
taking an IFN-α–based therapy but were not able to report the
speciﬁc form of IFN-based therapy (i.e., IFN-α alone, IFN-α þ RBV,
or IFN-α þ RBV þ TVR; as mentioned above, triple therapy
including boceprevir was not included in this study because
boceprevir is not approved for use in Japan) were excluded. A
total of 733 patients diagnosed with HCV (365 who were
untreated, 188 using IFN-α–based therapy, and 180 using liver
protectants, a common treatment for HCV in Japan) met all
inclusion and exclusion criteria and completed the survey. Liver
protectants (e.g., ursodeoxycholic acid and glycrrhizin) are pre-
scriptive palliative remedies common in Japan, which are used as
treatments to improve liver dysfunction for those who are IFN-α
intolerable or who choose not to receive IFN-α therapies. A priori
minimums were set for each of these groups to ensure sufﬁcient
statistical power for comparisons (i.e., 350 untreated, 150 IFN-α–
based therapy, 175 liver protectants), and so these sample sizes
were not intended to provide information on the natural preva-
lence of these groups.
Study Measures
Treatment usage
Respondents were categorized on the basis of whether they were
currently using an IFN-α–based therapy regardless of any other
treatments, liver protectants, or whether they were untreated.
Patient characteristics
All respondents provided data on sex, age, education, annual
household income, general health history (smoking behavior,
exercise behavior, height and weight [which was converted into
a body mass index category], and comorbidities using the
Charlson comorbidity index [CCI] [20]), and HCV disease history
(years diagnosed, genotype, viral load).
Adverse events
AEs were assessed only among respondents using IFN-α–based
therapy (“Some people who take prescription hepatitis C medi-
cation experience side effects as a result of the medication. To
what degree do you experience each of the following side effects
when you take [IFN-α alone, IFN-α þ RBV, or IFN-α þ RBV þ TVR
depending upon the patient’s current regiment]?”). Patients then
rated the following AEs as either “none,” “mild,” “moderate,”
“severe,” and “very severe”: fatigue, ﬂu-like symptoms, depres-
sion, dyspnea, muscle weakness, anemia, headache, skin rash,
nausea, dysgeusia, and insomnia. Only the presence (a rating of
“mild” to “very severe”) versus absence (a rating of “none”) of
each AE was considered in this study.
Quality of life
The Hepatitis Quality of Life Questionnaire (HQLQ), version 2
(HQLQv2), was used to assess both generic and disease-speciﬁc
elements of quality of life [21]. The HQLQ includes the Short
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aspects of health status) as well as additional hepatitis-related
items. Speciﬁcally, there are two generic health summary scores
(physical component summary [PCS] and mental component
summary [MCS] scores), eight generic health domain scores
(bodily pain, vitality, physical functioning, physical role limita-
tions, general health, mental health, social functioning, and
emotional role limitations), and four hepatitis-speciﬁc health
domain scores (health distress, positive well-being, hepatitis
distress, and hepatitis limitations). For all summary and domain
scores, higher scores indicate greater quality of life. For generic
summary and domain scores, differences between groups of 3
and 5 points, respectively, represent clinically meaningful differ-
ences [22]. No well-established standard for clinically mean-
ingful differences currently exists for hepatitis-speciﬁc domain
scores.
Work productivity
Work productivity and impairment was assessed using the Work
Productivity and Activity Impairment questionnaire [23]. Four
subscales (absenteeism, presenteeism, overall works impair-
ment, and activity impairment) are generated in the form of
percentages, with higher values indicating greater impairment.
Although only those patients currently employed will have data
on absenteeism, presenteeism, and overall work impairment, all
patients have data on activity impairment.
Resource use
Health care utilization was deﬁned by the number of health care
provider visits, the presence of an emergency room (ER) visit, and
the presence of a hospitalization. All events, which were total
events and not speciﬁc to HCV, were recalled on the basis of the
past 6 months.
Medication satisfaction
The Treatment Satisfaction Questionnaire for Medication, ver-
sion 2, was used to assess satisfaction with hepatitis medications
[24]. This 11-item instrument includes four subscales: effective-
ness, tolerability, convenience, and global satisfaction.
Medication adherence
Medication adherence was assessed using the eight-item version
of the Morisky Medication Adherence Scale (MMAS-8) [25].
Adapted speciﬁcally for HCV treatments, the MMAS-8 assess
the degree to which patients have been adherent with their
medications. A total score is categorized into low, medium, and
high adherence.
Statistical Analyses
Demographic and health history variables were compared among
respondents who were currently using an IFN-α–based therapy,
using liver protectants, or who were untreated. Differences were
examined using chi-square tests and one-way analyses of var-
iance (the latter were used regardless of whether there were two
or three analysis groups to compare).
Two separate comparisons were made to examine the burden
of IFN-α treatment. First, patients currently using IFN-α (n ¼ 188)
were compared with all other patients not using IFN-α (n ¼ 545;
including those who were currently using a liver protectant).
Second, patients using IFN-α (n ¼ 188) were also compared with
only those patients who were untreated (n ¼ 365). Both compar-
isons were made with respect to the MCS and PCS scores and all
four hepatitis-speciﬁc domains from the HQLQv2 using general
linear models, all measures of the Work Productivity and Activity
Impairment and the number of physician visits using generalizedlinear models (specifying a negative binomial distribution and a
log-link function), and ER visits and hospitalizations using logis-
tic regressions. All models adjusted for age, sex, and the CCI.
Adjusted means from these models were produced and com-
pared on the basis of the signiﬁcance of the treatment group
variable in the regression model.
The burden of individual AEs was examined only among
those using IFN-α–based treatment by comparing those with a
given AE versus those without a given AE. All comparisons were
made with respect to MCS and PCS scores and all four hepatitis-
speciﬁc domains from the HQLQv2 using general linear models,
all measures of the Work Productivity and Activity Impairment
and the number of physician visits using generalized linear
models (specifying a negative binomial distribution and a log-
link function), and ER visits and hospitalizations using logistic
regressions. All models adjusted for age, sex, and the CCI.
Adjusted means from these models were produced and com-
pared on the basis of the signiﬁcance of the AE variable in the
regression model. In addition, differences in treatment satisfac-
tion (all four subscales of the Treatment Satisfaction Question-
naire for Medication, version 2) and adherence scores (low vs.
medium vs. high levels of adherence according to the MMAS-8)
were examined as a function of the presence versus absence of
each individual AE.
Analyses were conducted in SASv9.2; the cutoff for statistical
signiﬁcance was a priori set at P o 0.05.Results
Sample Demographic Characteristics and Health History
A total of 188 (25.65%) respondents were currently using an IFN-
α–based therapy, 180 (24.56%) respondents were currently using a
liver protectant without IFN-α–based therapy, and the remaining
365 (49.80%) respondents were not currently treated. Across the
sample, most respondents were men (68.76%) with a mean age of
55.02  10.86 years (Table 1). Nearly a ﬁfth (18.28%) of all
respondents were elderly (i.e., 65 years old or older). This did
vary signiﬁcantly by treatment group as current patients using
IFN-α were the youngest (mean ¼ 51.79 years old; 12.77% elderly)
followed by those untreated (mean ¼ 55.01 years old; 16.99%
elderly) followed by liver protectant users (mean ¼ 58.43 years
old; 26.67% elderly). Even despite the negative skewness of the
age distribution, the majority (62.48%) of the patients were
currently employed.
The CCI was highest among patients using IFN-α (mean ¼
1.13) compared with those using liver protectants (mean ¼ 0.77)
and untreated patients (mean ¼ 0.62). Patients on liver protec-
tants were signiﬁcantly more likely to report long-term compli-
cations of HCV infection such as cirrhosis (20.56% including
compensated, decompensated, and unknown cirrhosis vs. 7.45%
and 4.66% for patients using IFN-α and those untreated, respectively)
and hepatocellular carcinoma (8.89% vs. 3.19% and 3.56% for
patients using IFN-α and those untreated, respectively) (both Po.05).
Effect of IFN-α–Based Therapy on Health-Related Quality of
Life, Work Impairment, and Health Care Resource Use
Adjusting for confounding variables, patients using IFN-α–based
therapy reported signiﬁcantly lower levels of PCS and MCS, the
latter of which exceeded the threshold for a clinically relevant
effect, as well as lower health distress, hepatitis limitations, and
hepatitis distress (see Table 2). No differences were observed with
respect to positive well-being. Patients using IFN-α–based therapy
also reported signiﬁcantly greater overall work impairment and
physician visits in the past 6 months than did those who were
Table 1 – Sociodemographic characteristics and health history differences among treatment groups.
Total
(N ¼ 733)
IFN-α
(N ¼ 188)
Liver protectant
(N ¼ 180)
Untreated
(N ¼ 365)
P
Male, n (%) 504 (68.76) 136 (72.34) 139 (77.22) 229 (62.74) 0.001
Age (y), mean  SD 55.02  10.86 51.79  12.68 58.43  9.54 55.01  9.94 o0.001
Age group (y), n (%) o0.001
o40 59 (8.05) 29 (15.43) 5 (2.78) 25 (6.85)
40–49 147 (20.05) 36 (19.15) 28 (15.56) 83 (22.74)
50–59 263 (35.88) 70 (37.23) 60 (33.33) 133 (36.44)
60–69 198 (27.01) 40 (21.28) 64 (35.56) 94 (25.75)
70þ 66 (9.00) 13 (6.91) 23 (12.78) 30 (8.22)
Education, n (%) 0.435
Junior high school 28 (3.82) 7 (3.72) 9 (5.00) 12 (3.29)
High school 239 (32.61) 49 (26.06) 61 (33.89) 129 (35.34)
2-y college 58 (7.91) 13 (6.91) 15 (8.33) 30 (8.22)
4-y college 294 (40.11) 84 (44.68) 73 (40.56) 137 (37.53)
Graduate school 40 (5.46) 14 (7.45) 9 (5.00) 17 (4.66)
Professional school 74 (10.10) 21 (11.17) 13 (7.22) 40 (10.96)
Annual household income (¥), n (%) 0.076
o3,000,000 164 (22.37) 30 (15.96) 54 (30.00) 80 (21.92)
3,000,000–o5,000,000 230 (31.38) 58 (30.85) 49 (27.22) 123 (33.70)
5,000,000–o8,000,000 163 (22.24) 47 (25.00) 36 (20.00) 80 (21.92)
8,000,000 or more 129 (17.60) 42 (22.34) 29 (16.11) 58 (15.89)
Decline to answer 47 (6.41) 11 (5.85) 12 (6.67) 24 (6.58)
Currently employed, n (%) 458 (62.48) 138 (73.40) 102 (56.67) 218 (59.73) 0.001
Body mass index category, n (%) 0.490
Underweight 56 (7.64) 18 (9.57) 12 (6.67) 26 (7.12)
Normal weight 504 (68.76) 121 (64.36) 132 (73.33) 251 (68.77)
Obese 163 (22.24) 47 (25.00) 35 (19.44) 81 (22.19)
Unknown 10 (1.36) 2 (1.06) 1 (0.56) 7 (1.92)
Exercised in past month, n (%) 361 (49.25) 95 (50.53) 95 (52.78) 171 (46.85) 0.394
Alcohol use, n (%) 438 (59.75) 112 (59.57) 81 (45.00) 245 (67.12) o0.001
Smoking behavior, n (%) 0.001
Current smoker 207 (28.24) 74 (39.36) 39 (21.67) 94 (25.75)
Former smoker 232 (31.65) 51 (27.13) 67 (37.22) 114 (31.23)
Never smoked 294 (40.11) 63 (33.51) 74 (41.11) 157 (43.01)
Charlson comorbidity index 0.79  1.88 1.13  3.16 0.77  1.15 0.62  1.11 0.009
IFN, interferon.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 5 0 – 5 8 53untreated. In addition, the odds of visiting the ER and being
hospitalized for patients using IFN-α–based therapy were more
than four times that of untreated patients. Similar effects were
observed when comparing patients using IFN-α–based therapyTable 2 – Summary of adjusted effects between those wi
Outcome IFN-α– based therapy No I
Physical component summary 50.158*
Mental component summary 44.309*
Health distress 66.500*
Positive well-being 48.351
Hepatitis limitations 68.457*
Hepatitis distress 73.147*
Overall work impairment, % 32.554
Activity impairment, % 30.447*
Number of physician visits 14.679
ER visit (Z1) (odds ratio) 4.635*
Hospitalization (Z1) (odds ratio) 2.780*
ER, emergency room; IFN, interferon.
* P o 0.05 relative to those without IFN-α–based therapy/untreated.and all those not using IFN-α–based therapy; however, overall
work impairment and the number of physician visits were not
signiﬁcantly different (32.55% vs. 26.36% and 14.68 vs. 11.77,
respectively).th and without IFN-α–based therapy.
FN-α–based therapy IFN-α–based therapy Untreated
51.547 50.126* 52.036
47.400 44.121* 47.969
72.446 66.333* 74.560
48.385 48.739 47.157
82.257 68.392* 84.207
83.052 72.895* 86.646
26.358 32.729* 25.643
24.835 30.759* 23.745
11.769 14.506* 8.363
7.246*
4.052*
9.04%
43.09%
45.21%
54.79%
55.85%
57.45%
59.57%
60.64%
61.70%
72.87%
78.72%
0% 20% 40% 60% 80% 100%
Insomnia
Dysgeusia
Nausea
Skin rash
Headache
Anemia
Muscle weakness
Shortness of breath
Feeling depressed or sad
Flu-like symptoms
Fatigue
Fig. 1 – Prevalence of AEs reported by patients using IFN-α (N ¼ 188). AE, adverse events; IFN-α, Pegylated-Interferon-α.
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The mean number of AEs per patient on IFN-α–based therapy was
6.05  3.33. In order of prevalence, the AEs reported by at least
half of the patients included fatigue (79%), ﬂu-like symptoms
(73%), depression/sadness (62%), dyspnea (62%), muscle weak-
ness (60%), anemia (57%), headache (56%), and skin rash (55%)
(see Fig. 1).Table 3 – Adjusted health-related quality-of-life differen
AEs Generic quality-of-life summary scores
Physical component
summary
Mental component
summary
Anemia 49.333 41.881*
No anemia 50.481 45.320
Fatigue 48.980* 41.955*
No fatigue 52.935 48.486
Depression 48.974* 39.866*
No
depression
51.187 48.949
Skin rash 48.360* 40.093*
No skin rash 51.592 47.284
Flu-like
symptoms
48.946* 41.795*
No ﬂu-like
symptoms
52.171 47.505
Dyspnea 48.098* 40.577*
No dyspnea 52.475 47.607
Muscle
weakness
48.214* 40.056*
No muscle
weakness
52.189 48.190
Headache 48.214* 39.715*
No headache 51.854 47.935
Note. All models adjusted for age, sex, and comorbidities.
AE, adverse events.
* P o 0.05 relative to those without AEs.Effect of AEs on Health-Related Quality of Life, Work
Impairment, and Health Care Resource Use
For each AE, those who experienced the event and those who
did not were compared with respect to health outcomes adjust-
ing for confounding variables (see Table 3). With the exception
of anemia, all AEs were associated with signiﬁcant decrements
in the PCS score. Clinically relevant differences were observedces between those with and without AEs.
Hepatitis-speciﬁc domains
Health
distress
Positive
well-being
Hepatitis
limitations
Hepatitis
distress
60.438* 49.572 61.672* 66.544*
69.033 47.953 73.659 77.603
59.431* 50.166 63.588* 67.728*
81.356 44.135 78.558 84.28
54.661* 51.652 59.473* 62.631*
79.296 44.423 78.534 85.135
53.981* 52.57* 58.355* 61.703*
76.352 44.415 76.974 82.819
59.351* 51.121 62.717* 66.603*
76.843 42.871 77.668 83.734
56.54* 52.114* 61.072* 64.466*
75.736 43.905 75.556 81.701
54.461* 52.526* 57.841* 62.52*
78.295 43.515 79.937 84.115
54.649* 53.972* 59.618* 61.15*
76.047 42.445 75.825 84.027
Table 4 – Adjusted work impairment and healthcare resource use differences between those with and
without AEs.
AEs Adjusted means Odds ratios
Overall work impairment Physician visits ER visit Hospitalization
Anemia 36.207 17.446*
1.42 4.23*No anemia 30.048 11.084
Fatigue 38.862* 16.743*
1.45 5.75*No fatigue 19.518 7.293
Depression 44.694* 15.488
1.12 1.07No depression 19.035 13.488
Skin rash 42.363* 18.417*
2.66* 2.49*No skin rash 22.993 10.274
Flu-like symptoms 38.525* 17.370*
0.88 4.41*No ﬂu-like symptoms 23.434 7.702
Dyspnea 42.270* 19.190*
2.44 5.84*No dyspnea 22.380 7.995
Muscle weakness 42.074* 18.439*
3.70* 2.49*No muscle weakness 23.025 9.255
Headache 43.844* 19.031*
0.88 3.50*No headache 21.205 9.516
Note. All models adjusted for age, sex, and comorbidities.
AE, adverse events; ER, emergency room.
* P o 0.05 relative to those without AEs.
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51.59), ﬂu-like symptoms (48.95 vs. 52.17), dyspnea (48.10 vs.
52.48), muscle weakness (48.21 vs. 52.19), and headache (48.21 vs.
51.85) (all P o 0.05). All AEs were associated with signiﬁcant and
clinically relevant decrements in the MCS score (all P o.05). The
largest effects were observed for depression (39.87 vs. 48.95),
headache (39.72 vs. 47.94), and muscle weakness (40.06 vs. 48.19)
(all P o 0.05).
AEs were also signiﬁcantly associated with decrements in
hepatitis-speciﬁc domains (see Table 3). Interestingly, no AE
was associated with poorer positive well-being and, in fact, for
skin rash, dyspnea, muscle weakness, and headache, the
presence of the AE was associated with higher positive well-
being (though scores for all groups were quite low, o54 on a 0–
100 scale). The remaining subscales had the expected pattern
of lower scores among those who reported an AE. Aside from
anemia, all other AEs were associated with comparable decre-
ments in health distress (between 17.49 and 24.64 points
lower; all P o 0.05). Both hepatitis limitations and hepatitis
distress were signiﬁcantly lower among those with each
individual AE; patients reporting depression, skin rash, and
muscle weakness reported the largest decrements in these
domain scores.
Among patients using IFN-α–based therapy and who were
employed, the presence of all AEs (with the exception of
anemia) was associated with signiﬁcantly higher overall work
impairment (see Table 4). Indeed, the level of work impairment
was approximately double for those reporting each AE and, in
absolute levels, represented 40% of the work time that was
missed or rendered ineffective because of health. A greater
number of physician visits were also reported for all those
with AEs, often more than double the number of visits without
AEs, with the exception of depression, which was not signiﬁcant.
Only skin rash (odds ratio ¼ 2.66, P o 0.05) and muscle weakness
(odds ratio ¼ 3.70, P o 0.05) were associated with an increased
likelihood of an ER visit. All AEs, with the exception of depression,
were associated with an increased likelihood of a hospitalization
(all P o 0.05).Adherence and Satisfaction with and Without AEs
The presence of AEs was also signiﬁcantly associated with
decreased medication satisfaction and adherence (see Table 5).
Nausea (48.92 vs. 65.05, P o 0.05), fatigue (54.34 vs. 70.42, P o 0.05),
and skin rash (51.05 vs. 65.88, P o 0.05) were most strongly related
with decrements in global satisfaction though all other AEs were
also associated with lower scores with the exception of anemia
(55.94 vs. 60.21, P ¼ nonsigniﬁcant) and, as previously discussed,
insomnia (59.31 vs. 57.60, P ¼ nonsigniﬁcant). Several AEs were also
signiﬁcantly related to a reduced probability of having high levels of
adherence: depression (25.86% vs. 48.61%, P o 0.05), ﬂu-like symp-
toms (28.47% vs. 50.98%, Po 0.05), skin rash (25.24% vs. 45.88%, Po
0.05), fatigue (30.41% vs. 50.00%, Po 0.05), nausea (24.71% vs.42.72%,
P o 0.05), and headache (26.67% vs. 44.58%, P o 0.05).Discussion
The overall objective of this study was to quantify the patient-
reported burden of IFN-α treatments and AEs among patients in
Japan. This investigation is particularly relevant for Japan given
the aging HCV population who may be even less likely to tolerate
the various AEs of IFN-α therapy [13]. Consistent with previous
studies in which patients with HCV in Japan were 10 to 15 years
older than patients with HCV in the United States [26–28],
approximately a ﬁfth of our sample was 65 years or older. The
age distribution was slightly younger than in recent studies [29]
and may reﬂect differences in the sampling method.
As might be expected, only 12.77% of the patients currently
using IFN-α were elderly, suggesting that the burden of IFN-α may
be altering prescribing patterns. Interestingly, the IFN-α group
(although the youngest) was also the most saddled with comorbid-
ities. Although more extensive research would be required, it is
possible that age is a more important deterrent to administering
IFN-α than comorbidities themselves. Indeed, Iwasaki et al. [13]
concluded that age was an important factor in the safety of IFN-α
Table 5 – Relationships between AEs and side effects and treatment satisfaction.
TSQM: Side
effects
subscale*
TSQM:
Effectiveness
subscale
TSQM:
Convenience
subscale
TSQM: Global
satisfaction
subscale
MMAS: Total score (%)
Mean Mean Mean Mean
Low
adherence
Medium
adherence
High
adherence
P
Anemia (n ¼ 108) 46.37 52.47† 52.62† 55.94 29.63 41.67 28.70
0.111No anemia (n ¼ 80) 55.75 62.29 60.14 60.21 20.00 37.50 42.50
Fatigue (n ¼ 148) 47.46† 53.15† 52.67† 54.34† 29.05 40.54 30.41
0.031No fatigue (n ¼ 40) 68.75 69.58 67.50 70.42 12.50 37.50 50.00
Depression (n ¼ 116) 40.44† 51.58† 50.19† 52.95† 34.48 39.66 25.86
o0.001No depression (n ¼ 72) 69.87 64.81 64.89 65.51 11.11 40.28 48.61
Skin rash (n ¼ 103) 45.29† 48.46† 50.70† 51.05† 30.10 44.66 25.24
0.012No skin rash (n ¼ 85) 57.94 66.57 62.03 65.88 20.00 34.12 45.88
Flu-like symptoms (n ¼ 137) 45.79† 52.25† 52.19† 54.68† 29.20 42.34 28.47
0.012No ﬂu-like symptoms
(n ¼ 51)
67.05 68.46 65.58 66.01 15.69 33.33 50.98
Dyspnea (n ¼ 114) 44.22† 50.00† 51.22† 52.92† 25.44 43.86 30.70
0.301No dyspnea (n ¼ 74) 61.32 66.89 62.91 65.2 25.68 33.78 40.54
Muscle weakness (n ¼ 112) 43.26† 50.07† 50.45† 53.05† 30.36 38.39 31.25
0.168No muscle weakness
(n ¼ 76)
64.04 66.34 63.74 64.69 18.42 42.11 39.47
Headache (n ¼ 105) 44.44† 49.84† 50.53† 52.22† 33.33 40.00 26.67
0.007No headache (n ¼ 83) 58.33 65.26 62.52 64.76 15.66 39.76 44.58
Nausea (n ¼ 85) 39.05† 46.67† 47.65† 48.92† 36.47 38.82 24.71
0.003No nausea (n ¼ 103) 61.11 64.89 62.57 65.05 16.50 40.78 42.72
AE, adverse event; MMAS, Morisky Medication Adherence Scale; TSQM, Treatment Satisfaction Questionnaire for Medication.
* Only among those who reported experiencing side effects within the TSQM instrument (N ¼ 127).
† P o 0.05 relative to those without AEs.
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were more likely to require dose reductions or discontinue therapy.
The results of the current study demonstrate the immense
burden of IFN-α treatment across various humanistic and eco-
nomic domains. In terms of health-related quality of life, patients
using IFN-α reported both poorer MCS and PCS scores on the
HQLQ relative to those not using IFN-α (i.e., those using liver
protectants) and those untreated. Speciﬁcally, the clinically
relevant burden of IFN-α on mental health was comparable to
the burden of nocioceptive pain in Japan [30] and greater than the
burden of type 2 diabetes, obesity, and hypertension in Japan [31].
The lack of research examining the health-related quality of life
of patients with HCV undergoing IFN-α treatment in Japan does
not allow us to compare the current study ﬁndings with those of
other studies; however, the lower PCS and MCS scores during
IFN-α treatment are consistent with previous studies conducted
in Western countries [15,32].
Patients using IFN-α treatment reported nearly 30% more work
impairment than did untreated patients. Patients using IFN-α also
reported more health care resource utilization than did both all
other patients not using IFN-α and patients who were untreated.
Research studies examining the indirect and direct costs (e.g.,
work productivity and health care resource use) for treated
patients with HCV is scarce, even in Western countries. The
handful of studies examining this topic in the United States found
evidence of work impairments among patients with HCV treated
with IFN-α [18,33,34]. To the best of our knowledge, the current
study is the ﬁrst to demonstrate both work productivity loss and
increased health care resource use among patients with HCV
treated with IFN-α in Japan. The current study also highlights the
importance of factoring in the indirect costs (i.e., work productiv-
ity losses) even among an older patient sample when estimating
the total societal burden. It should be emphasized that the intent
of this analysis was to determine the overall burden of treatment
and not the overall effectiveness of these treatments. Better
health outcomes, such as higher quality of life, among those
using liver protectants and those untreated does not imply that
those treatments have superior clinical effectiveness.
The burden of IFN-α is likely attributed to the treatment’s
various AEs. Indeed, most AEs were reported by more than half
the IFN-α subsample with an average of six AEs per patient.
Consistent with published studies examining the AEs of IFN-α,
the most commonly reported AEs included fatigue, ﬂu-like
symptoms, depression/sadness, dyspnea, muscle weakness, ane-
mia, headache, and skin rash [9,35]. Although the burden varied
by AE, in all cases there was a signiﬁcant (and often clinically
relevant) association with health-related quality of life, work
impairment, and health care resource use events. The burden
of AEs on health-related quality of life was particularly strong
and more speciﬁcally, the mental health–related aspects were
generally the most affected as indicated by the largest effect
sizes. These results suggest that although AEs can take a physical
toll on the patient, their effect on the mental health of the patient
may be even more burdensome.
IFN-α–related AEs were also associated with poorer treatment
satisfaction and adherence. The effects were among the strongest
for depression in that only a quarter of patients with depression
reported high adherence compared with nearly half of those
without depression. This was consistent with a study conducted
by Fried et al. [36] in which 32% to 43% of the patients on IFN-α
combination therapy discontinued treatment because of an AE
and 22% to 30% did so as a result of depression. These ﬁndings on
the relationships between AEs with both satisfaction and non-
adherence suggest signiﬁcant unmet needs for IFN-α–based
therapy. The lack of adherence to treatment may ultimately
contribute to poorer effectiveness because patients discontinue
treatment before realizing the beneﬁts [37].There are important implications for reducing HCV patients’
AE burden during treatment. The reduction of AEs during treat-
ment would likely lead to better health-related quality of life and
greater treatment adherence, ultimately contributing to an
improved likelihood of treatment success. As the current study
suggests, AEs are also associated with decrements in work
productivity and increases in the use of health care resources,
which leads to an economic burden on a societal level. With the
health burden of HCV in Japan expected to rise over the next
several decades as a result of its aging patient population [7],
there is a substantial need for improved treatments with more
tolerable proﬁles.
There are several limitations to the current study that should
be noted. The current study was a self-reported survey and there
was no clinical veriﬁcation of HCV diagnosis among patients. The
self-reported nature of the study also could have introduced
additional measurement error (due to recall bias) into such
variables as health care resource utilization or adherence. Future
research could overcome this limitation by combining self-
reported data with clinical data to accurately capture the meas-
ures in question. Given that the survey was conducted via the
Internet, the extent to which the sample generalizes to the
population is unclear. It is possible that certain HCV subpopula-
tions may have been underrepresented.
Regardless of these limitations, this study also offers several
strengths. Only through self-report is it possible to understand
health-related quality of life, symptomatic AEs, work impair-
ments, and treatment satisfaction. These constructs are vital for
documenting the overall treatment burden and understanding
how treatment advances (which, presumably, would reduce the
prevalence of AEs) would subsequently affect patient-reported
outcomes, adherence, and discontinuation. The current study
adds considerably to the literature because no study to our
knowledge has examined these constructs in Japan.Conclusions
The present study suggests that there is a signiﬁcant patient
burden with IFN-α treatment in Japan. This burden is likely
explained by highly prevalent AEs, which are each associated
with decrements in health-related quality of life, work produc-
tivity, and increases in health care resource use. Overall levels of
satisfaction and adherence are low and partially explained by the
presence of AEs; indeed, discontinuation is often attributed to the
presence of AEs. Perhaps as a result, IFN-α therapy is uncommon
among the elderly. Collectively, these results suggest that effec-
tive, non-IFN-α–based treatment may alleviate a substantial
humanistic burden and could be associated with greater rates
of patient satisfaction and adherence.
Source of ﬁnancial support: Bristol-Myers Squibb funded
this study.
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